415 related articles for article (PubMed ID: 27469901)
1. Observational registry of sorafenib use in clinical practice across Child-Pugh subgroups: The GIDEON study.
Marrero JA; Kudo M; Venook AP; Ye SL; Bronowicki JP; Chen XP; Dagher L; Furuse J; Geschwind JH; de Guevara LL; Papandreou C; Takayama T; Sanyal AJ; Yoon SK; Nakajima K; Lehr R; Heldner S; Lencioni R
J Hepatol; 2016 Dec; 65(6):1140-1147. PubMed ID: 27469901
[TBL] [Abstract][Full Text] [Related]
2. GIDEON (Global Investigation of therapeutic DEcisions in hepatocellular carcinoma and Of its treatment with sorafeNib): second interim analysis.
Lencioni R; Kudo M; Ye SL; Bronowicki JP; Chen XP; Dagher L; Furuse J; Geschwind JF; de Guevara LL; Papandreou C; Takayama T; Yoon SK; Nakajima K; Lehr R; Heldner S; Sanyal AJ
Int J Clin Pract; 2014 May; 68(5):609-17. PubMed ID: 24283303
[TBL] [Abstract][Full Text] [Related]
3. [Therapeutic decisions in the treatment of hepatocellular carcinoma and patterns of sorafenib use. Results of the international observational GIDEON trial in Spain].
Turnes J; Díaz R; Hernandez-Guerra M; Gómez M; Castells L; Bustamante J; Espinosa MD; Fernández-Castroagudín J; Serrano T; Rendón P; Andrade R; Salgado M; Arenas J; Vergara M; Sala M; Polo BA; Granizo IM; Gonzálvez ML; Viudez A
Gastroenterol Hepatol; 2015 Apr; 38(4):263-73. PubMed ID: 25583146
[TBL] [Abstract][Full Text] [Related]
4. Safety and efficacy of sorafenib in Japanese patients with hepatocellular carcinoma in clinical practice: a subgroup analysis of GIDEON.
Kudo M; Ikeda M; Takayama T; Numata K; Izumi N; Furuse J; Okusaka T; Kadoya M; Yamashita S; Ito Y; Kokudo N
J Gastroenterol; 2016 Dec; 51(12):1150-1160. PubMed ID: 27106231
[TBL] [Abstract][Full Text] [Related]
5. Regional differences in sorafenib-treated patients with hepatocellular carcinoma: GIDEON observational study.
Kudo M; Lencioni R; Marrero JA; Venook AP; Bronowicki JP; Chen XP; Dagher L; Furuse J; Geschwind JF; Ladrón de Guevara L; Papandreou C; Sanyal AJ; Takayama T; Yoon SK; Nakajima K; Lehr R; Heldner S; Ye SL
Liver Int; 2016 Aug; 36(8):1196-205. PubMed ID: 26901163
[TBL] [Abstract][Full Text] [Related]
6. Safety and efficacy of sorafenib therapy in patients with hepatocellular carcinoma: final outcome from the Chinese patient subset of the GIDEON study.
Ye SL; Chen X; Yang J; Bie P; Zhang S; Liu F; Liu L; Zhou J; Dou K; Hao C; Shao G; Xia Q; Chen Y; Yang J; Deng X; Liu Y; Yuan Y; Fu Z; Nakajima K; Yip CS; Lu Z
Oncotarget; 2016 Feb; 7(6):6639-48. PubMed ID: 26735891
[TBL] [Abstract][Full Text] [Related]
7. Real-Life Experience of Sorafenib Treatment for Hepatocellular Carcinoma in Korea: From GIDEON Data.
Kim DY; Kim HJ; Han KH; Han SY; Heo J; Woo HY; Um SH; Kim YH; Kweon YO; Lim HY; Yoon JH; Lee WS; Lee BS; Lee HC; Ryoo BY; Yoon SK
Cancer Res Treat; 2016 Oct; 48(4):1243-1252. PubMed ID: 26910470
[TBL] [Abstract][Full Text] [Related]
8. Safety assessment of sorafenib in Chinese patients with unresectable hepatocellular carcinoma: subgroup analysis of the GIDEON study.
Ye SL; Yang J; Bie P; Zhang S; Chen X; Liu F; Liu L; Zhou J; Dou K; Hao C; Shao G; Xia Q; Chen Y; Yang J; Deng X; Liu Y; Yuan Y; Fu Z; Nakajima K; Lv Z
BMC Cancer; 2018 Mar; 18(1):247. PubMed ID: 29499662
[TBL] [Abstract][Full Text] [Related]
9. [Therapeutic decisions and treatment with sorafenib in hepatocellular carcinoma: final analysis of GIDEON study in Italy].
D'Angelo S; Germano D; Zolfino T; Sansonno D; Giannitrapani L; Benedetti A; Montesarchio V; Attili A; Buonadonna A; Barni S; Gasbarrini A; Burlone ME; Cillo U; Marenco S; Villa E; Giovanis P; Proserpio I; Saitta C; Magini G; Cengarle R; Fava G; Cuttone F; Calvani N; Angelico M; Di Costanzo F; Noto A; Poggi G; Marignani M; Cascinu S; Amoroso D; Palmieri V; Massa E; Crocè LS; Picardi A; Tumulo S; Erminero C; Lencioni R; Lorusso V
Recenti Prog Med; 2015 May; 106(5):217-26. PubMed ID: 25994538
[TBL] [Abstract][Full Text] [Related]
10. First interim analysis of the GIDEON (Global Investigation of therapeutic decisions in hepatocellular carcinoma and of its treatment with sorafeNib) non-interventional study.
Lencioni R; Kudo M; Ye SL; Bronowicki JP; Chen XP; Dagher L; Furuse J; Geschwind JF; Ladrón de Guevara L; Papandreou C; Sanyal AJ; Takayama T; Yoon SK; Nakajima K; Cihon F; Heldner S; Marrero JA
Int J Clin Pract; 2012 Jul; 66(7):675-83. PubMed ID: 22698419
[TBL] [Abstract][Full Text] [Related]
11. TACE Treatment in Patients with Sorafenib-treated Unresectable Hepatocellular Carcinoma in Clinical Practice: Final Analysis of GIDEON.
Geschwind JF; Kudo M; Marrero JA; Venook AP; Chen XP; Bronowicki JP; Dagher L; Furuse J; Ladrón de Guevara L; Papandreou C; Sanyal AJ; Takayama T; Ye SL; Yoon SK; Nakajima K; Lehr R; Heldner S; Lencioni R
Radiology; 2016 May; 279(2):630-40. PubMed ID: 26744927
[TBL] [Abstract][Full Text] [Related]
12. Safety and effectiveness of sorafenib in Japanese patients with hepatocellular carcinoma in daily medical practice: interim analysis of a prospective postmarketing all-patient surveillance study.
Kaneko S; Ikeda K; Matsuzaki Y; Furuse J; Minami H; Okayama Y; Sunaya T; Ito Y; Inuyama L; Okita K
J Gastroenterol; 2016 Oct; 51(10):1011-21. PubMed ID: 26931117
[TBL] [Abstract][Full Text] [Related]
13. HATT: a phase IV, single-arm, open-label study of sorafenib in Taiwanese patients with advanced hepatocellular carcinoma.
Lin SM; Lu SN; Chen PT; Jeng LB; Chen SC; Hu CT; Yang SS; Le Berre MA; Liu X; Mitchell DY; Prins K; Grevel J; Peña CA; Meinhardt G
Hepatol Int; 2017 Mar; 11(2):199-208. PubMed ID: 27909950
[TBL] [Abstract][Full Text] [Related]
14. Design and rationale for the non-interventional Global Investigation of Therapeutic DEcisions in Hepatocellular Carcinoma and Of its Treatment with Sorafenib (GIDEON) study.
Lencioni R; Marrero J; Venook A; Ye SL; Kudo M
Int J Clin Pract; 2010 Jul; 64(8):1034-41. PubMed ID: 20642705
[TBL] [Abstract][Full Text] [Related]
15. Exploring the efficacy and safety of single-agent sorafenib in a cohort of Italian patients with hepatocellular carcinoma.
Santini D; Addeo R; Vincenzi B; Calvieri A; Montella L; Silletta M; Caraglia M; Vespasiani U; Picardi A; Del Prete S; Tonini G
Expert Rev Anticancer Ther; 2012 Oct; 12(10):1283-8. PubMed ID: 23094801
[TBL] [Abstract][Full Text] [Related]
16. Sorafenib for non-selected patient population with advanced hepatocellular carcinoma: efficacy and safety data according to liver function.
Zugazagoitia J; Manzano A; Sastre J; Ladero JM; Puente J; Díaz-Rubio E
Clin Transl Oncol; 2013 Feb; 15(2):146-53. PubMed ID: 22875650
[TBL] [Abstract][Full Text] [Related]
17. Sorafenib: A Review in Hepatocellular Carcinoma.
Keating GM
Target Oncol; 2017 Apr; 12(2):243-253. PubMed ID: 28299600
[TBL] [Abstract][Full Text] [Related]
18. Clinical outcomes of patients with advanced hepatocellular carcinoma treated with sorafenib: a retrospective study of routine clinical practice in multi-institutions.
Lee SH; Song IH; Noh R; Kang HY; Kim SB; Ko SY; Lee ES; Kim SH; Lee BS; Kim AN; Chae HB; Kim HS; Lee TH; Kang YW; Lee JD; Lee HY
BMC Cancer; 2015 Apr; 15():236. PubMed ID: 25885683
[TBL] [Abstract][Full Text] [Related]
19. Liver function assessment according to the Albumin-Bilirubin (ALBI) grade in sorafenib-treated patients with advanced hepatocellular carcinoma.
Ogasawara S; Chiba T; Ooka Y; Suzuki E; Kanogawa N; Saito T; Motoyama T; Tawada A; Kanai F; Yokosuka O
Invest New Drugs; 2015 Dec; 33(6):1257-62. PubMed ID: 26462681
[TBL] [Abstract][Full Text] [Related]
20. The impact of patient and tumour baseline characteristics on the overall survival of patients with advanced hepatocellular carcinoma treated with sorafenib.
Wörns MA; Koch S; Niederle IM; Marquardt JU; Nguyen-Tat M; Gamstätter T; Schuchmann M; Schulze-Bergkamen H; Galle PR; Weinmann A
Dig Liver Dis; 2013 May; 45(5):408-13. PubMed ID: 23182599
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
